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Abstract
Background: There is currently a vast amount of evidence in the literature suggesting that matrix
metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are involved in the
pathogenesis of inflammatory airways diseases, such as asthma and COPD. Despite this, the
majority of reports only focus on single MMPs, often only in one model system. This study aimed
to investigate the profile of an extensive range of MMP/TIMP levels in three different pre-clinical
models of airways disease. These models each have a different and very distinct inflammatory
profile, each exhibiting inflammatory characteristics that are similar to that observed in asthma or
COPD. Since these models have their own characteristic pathophysiological phenotype, one would
speculate that the MMP/TIMP expression profile would also be different.
Methods: With the use of designed and purchased MMP/TIMP assays, investigation of rat MMP-2,
3, 714 and TIMP-14 mRNA expression was undertaken by Real Time PCR. The three rodent
models of airways disease investigated were the endotoxin model, elastase model, and the antigen
model.
Results: Intriguingly, we demonstrated that despite the distinct inflammatory profile observed by
each model, the MMP/TIMP expression profile is similar between the models, in that the same
MMPs/TIMPs were observed to be generally increased or decreased in all three models. It could
therefore be speculated that in a particular disease, it may be a complex network of MMPs, rather
than an individual MMP, together with inflammatory cytokines and other mediators, that results in
the distinct phenotype of inflammatory diseases, such as asthma and COPD.
Conclusion: We believe our data may provide key information necessary to understand the role
of various MMPs/TIMPs in different inflammatory airway diseases, and aid the development of more
selective therapeutics without the side effect profile of current broad-spectrum MMP inhibitors.
Background
Matrix metalloproteinases (MMPs) play a critical role in
inflammatory airways diseases, such as chronic obstruc-
tive pulmonary disease (COPD) [1-4], and asthma [5-8].
However, the precise role of MMPs in inflammation still
remains unclear although the role of this family of pro-
teases has been studied extensively in pre-clinical models
of airway inflammatory disease that share certain features
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of the human disease phenotype. Therefore, despite the
vast literature implicating the involvement of these pro-
teases in the pathogenesis of inflammatory diseases, many
of these reports only focus on the role of one particular
MMP, and often only in one model system. Hence, we
were interested in investigating the profile of a large range
of MMPs and their inhibitors, tissue inhibitors of metallo-
proteinases (TIMPs), in different inflammatory airways
disease conditions modelled by three distinct pre-clinical
models of inflammation. These three pre-clinical models:
evoked by antigen, endotoxin and elastase, each exhibit
their own distinct inflammatory characteristics that are
similar to that observed in human airways disease, for
example, increased eosinophils in asthma, and increased
neutrophils and lymphomononuclear cells in inflamma-
tory airways diseases, such as COPD. The antigen induced
allergic airway inflammation model has been demon-
strated to exhibit increased levels of eosinophils and
inflammatory cytokines [9,10]. In addition, this model
has also been demonstrated to have increased levels of
p65:DNA binding, used as a marker of NF-κB pathway
activation, and the antigen induced airway inflammation
was observed to be responsive to steroid treatment. Our
group has also demonstrated that this model exhibits a
steroid insensitive early asthmatic response (EAR), and a
steroid sensitive late asthmatic response (LAR). The endo-
toxin-driven model is predominantly neutrophilic in
nature, and additionally differs from the antigen model
because it is an innate response rather than an adaptive
one. It has been shown to have increased levels of inflam-
matory cytokines and p65:DNA binding after stimulation,
and we have also previously demonstrated the LPS
induced inflammation to be sensitive to steroid treatment
[11,12]. The third model we were interested in investigat-
ing in this study was the elastase induced experimental
emphysema model, which has been demonstrated to
exhibit an increase in lymphomononuclear cells and
inflammatory cytokines [13]. Interestingly, the inflamma-
tion observed in the elastase model was steroid resistant,
an aspect similar to that observed in emphysema/COPD.
Furthermore, there was no increase in levels of p65:DNA
binding at several selected time points after elastase treat-
ment. In addition, this steroid resistant model exhibited
aspects of airway remodelling, as average airspace area
were increased, and emphysema-like changes in lung
function were observed.
Since these three pre-clinical models each have different
and very distinct inflammatory characteristics, one would
speculate that the profile of MMPs and TIMPs involved
may vary between these models. This study adopted the
novel approach of elucidating the expression profile of a
range of MMPs and TIMPs with the use of assays for Taq-
Man Real Time PCR, in these three distinct pre-clinical
models of airways disease. We chose to use Real Time
PCR, since there is a limited range of investigational tech-
niques that are commercially available for the range of rat
MMPs and TIMPs investigated in this study. We believe
our data may provide key information necessary to under-
stand the role of various MMPs and TIMPs in different
inflammatory airway diseases, and aid the development
of more selective therapeutics without the side effect pro-
file of current broad-spectrum MMP inhibitors.
Methods
Male Brown Norway rats (200225 g), male Wistar rats
(175200 g) and male Sprague Dawley rats (260300 g)
were purchased from Harlan-Olac (Bicester, UK) and kept
for at least 5 days before initiating experiments. Food and
water were supplied ad libitum. UK Home Office guide-
lines for animal welfare based on the Animals (Scientific
Procedures) Act 1986 were strictly observed.
Brown Norway rats were sensitised on days 0, 14 and 21
with ovalbumin (100 μg, i.p.) administered with alumin-
ium hydroxide (100 mg, i.p.) and challenged with inhaled
ovalbumin (10 g/l, 30 minutes) or saline aerosol on day
28, similar to that outlined by Underwood et al., 2002
[10]. For the time course studies, BAL fluid were obtained
at various time points (2, 4, 6, 8, 12 and 24 hours), for
analysis of cellular inflammation, biomarker levels by
ELISA, and MMP-9 levels by zymography as outlined by
McCluskie et al., 2004 [14]. Lung lobes were obtained to
determine mRNA levels, as outlined by McCluskie et al.,
2004 [14]. The effect of an IkappaB kinase-2 (IKK-2)
inhibitor, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-
fluorophenyl)-3-thiophenecarboxamide) and budeso-
nide was investigated in this model. TPCA-1 (30 mg/kg,
prepared in DMSO (2%), CremophorEL (10%) and etha-
nol (5%) in water) (donated by GlaxoSmithKline) or
budesonide (3 mg/kg) (Sigma, UK) were orally dosed 2
hours before challenge, and 3, 8 and 12 hours after chal-
lenge. Budesonide, a commonly used steroid in man, was
used as a positive control in these in vivo experiments, as
it has previously been shown to inhibit LPS-induced neu-
trophilia in the rat [11]. This dosing regimen was used as
it was found to give adequate compound exposure as
assessed by pharmacokinetic studies and efficacy studies
[9]. The dosing regimen for budesonide has been vali-
dated in our previous studies [15,11]. BAL fluid and lung
lobes were taken 24 hours after challenge for analysis of
cellular inflammation. The level of NF-κB pathway activa-
tion was determined on the lung tissue using an Active
Motif kit which measures p65:DNA binding in accord-
ance with manufactures instructions.
Wistar rats were challenged with aerosolised endotoxin
free saline or LPS (0.3 mg/ml) for 30 minutes, as outlined
by [12]. For time course studies, BAL fluid was obtained
for analysis as described above, at various time points (1,Respiratory Research 2009, 10:72 http://respiratory-research.com/content/10/1/72
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Table 1: Table showing the sequences of designed and purchased rat primers and probes of MMPs investigated, the mRNA sequences 
used for the designs, and the conditions and optimised concentrations of each primer and probe.
Assay PUBMED Assession No Assay Efficiency Sequence
rat MMP-2 NM_031054 88.57% Assay on Demand Applied Biosystems  Rn01538174_m1
GATTCTGCCCAGAGACTGCTATGTC
rat MMP-3 NM_133523 95.04% Forward Primer 5' CCT CTA TGG ACC TCC CAC AGA A 3'
Probe 5' TAC CCA CCA AAT CTA ACT CTC TGG ACC 
CTG AG 3'
Reverse Primer 5' CGA AGG ACA AAG CAG AGC TAC AC 3'
rat MMP-7 NM_012864 104.02% Forward Primer 5' CGG CGG AGA TGC TCA CTT T 3'
Probe 5' ACA GGA AGT TCA CTC CTG AGT CCT CAC 
CAT C 3'
Reverse Primer 5' GCC AAG TTC ATG AGT GGC AAC 3'
rat MMP-8 NM_022221 96.15% Assay on Demand Applied Biosystems  Rn00573646_m1
GAAAACTGCTGAGAATTACCTACGA
rat MMP-9 NM_031055 99.79% Forward Primer 5' CCG AGA CCT GAA AAC CTC CAA 3'
Probe 5' ACA CAC AGC TGG CAG AGG ATT ACC TGT 
ACC 3'
Reverse Primer GCT GCC CGA GTG TAA CCA TAG 3'
rat MMP-10 NM_133514 94.89% Forward Primer 5' TCC TGG TGC TGC TGT GCT T 3'
Probe 5' CCG ATC TGC TCA GCA TAT CCT CTG CAT 3'
Reverse Primer 5' CTA GGT ATT GCT GAG CAA GAT CCA T 3'
rat MMP-11 NM_012980 95.63% Forward Primer 5' CCT GTG GAT GCA GCT TTT GAG 3'
Probe 5' CCA GAT TTG GTT CTT CCA AGG TGC TCA GTA 
C 3'
Reverse Primer 5' GGG CCT AGG ACT GGC TTC TC 3'
rat MMP-12 NM_053963 107.62% Assay on Applied Biosystems  Rn00588640_m1
Demand TTCAAGGCACAAACCTGTTCCTTGT
rat MMP-13 XM_217083 98.34% Forward Primer 5' CCA GTC TCT CTA TGG TCC AGG AGA T 3'
Probe 5' AGA CCC CAA CCC TAA GCA CCC CAA AAC 3'
Reverse Primer 5' TCG GAG ACT AGT AAT GGC ATC AAG 3'
rat MMP-14 NM_031056 97.42% Forward Primer 5' CCG CCA TGC AAA GGT TCT A 3'
Probe 5' CGA ATC GGC CTT GCC TGT CAC TTG 3'
Reverse Primer 5' CGC CTC ATA GCC TTC ATC GT 3'
rat TIMP-1 NM_053819 96.22% Forward Primer 5' CCA CCT TAT ACC AGC GTT ATG AGA 3'
Probe 5' CGT CGA ATC CTT TGA GCA TCT TAG TCA TCT 
TG 3'
Reverse Primer 5' CCG GAA ACC TGT GGC ATT T 3'
rat TIMP-2 NM_021989 98.5% Forward Primer 5' GCT GGA CGT TGG AGG AAA GA 3'
Probe 5' TCT CCT TCC GCC TTC CCT GCA ATT AGA TAT 
T 3'
Reverse Primer 5' GCA CAA TAA AGT CAC AGA GGG TAA TG 3'
rat TIMP-3 NM_012886 100.27% Forward Primer 5' GAA CGG AAG CGT GCA CAT G 3'
Probe 5' CCG ACA TCG TGA TCC GGG CC 3'
Reverse Primer 5' CCC TTC CTT CAC CAG CTT CTT 3'
rat TIMP-4 NM_080639 97.27% Forward Primer 5' TGC AGA GGG AGA GCC TGA A 3'
Probe 5' ACT GTG GCT GCC AAA TCA CCA CTT GC 3'
Reverse Primer 5' GCC AGT CCG TCC AGA GAC A 3'Respiratory Research 2009, 10:72 http://respiratory-research.com/content/10/1/72
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2, 4, 6, 8, 12 and 24 hours). For compound studies, TPCA-
1 or budesonide was administered using the dosing regi-
men as above, 1 hour before challenge, and 2 hours after
challenge. BAL fluid and lung lobes were taken 6 hours
after challenge for analysis of cellular inflammation, and
level of NF-κB pathway activation, as described above.
Using the elastase induced experimental emphysema
model previously characterised by our group [13], BAL
fluid and lung lobes were obtained for analysis as
described above for time course studies, at 2, 6, 24, 48, 72,
96 and 168 hours. For compound studies, TPCA-1 or
budesonide was administered using the dosing regimen as
above, 1 hour prior and 6, 22, 30 and 46 hours post
elastase insult. BAL fluid and lung lobes were taken 48
hours after challenge for analysis of cellular inflamma-
tion, and level of NF-κB pathway activation, as described
above.
MMP/TIMP mRNA levels by Real Time PCR
Total cellular RNA was isolated from all rat lung samples
using Tri Reagent (Sigma-Aldrich), following manufac-
turer's instructions. RNA samples were reverse transcribed
as outlined by [14]. Amplification and detection of MMPs
2, 3, 714 and TIMPs 14 mRNA was carried out in an ABI
PRISM 7700 sequence detection system (Applied Biosys-
tems), as outlined by [14], using designed, validated and
optimised primers and TaqMan probes or validated pre-
developed assays (Applied Biosystems) (Table 1). 18S
rRNA levels were simultaneously measured to normalise
for variations in sample loading. Due to the exponential
nature of PCR, the delta ct (Δct) values were converted to
a linear form, and written as 2-Δct. For graphing, 2-ΔCt val-
ues were multiplied by 106 and shown as relative units. 2-
Δct values of less than 0.10 × 106 were assigned as 'below
reliable detection limit' (BRDL).
Statistical analysis
Statistical significance was determined using an unpaired
t test with each independent group compared to the vehi-
cle control. If the variances of the two groups were signif-
icantly different then the Mann Whitney rank sum test
was used. A p-value of less than 0.05 was taken as signifi-
Table 2: BAL inflammatory cells in the three in vivo models of lung inflammation
Antigen Model LPS Model Elastase Model
Neutrophils LMN Eosinophils LMN Neutrophils Eosinophils
2 hrs Veh 0.4 ± 0.3 173.8 ± 16.1 1 hr Veh 0.0 0.0 106.3 ± 20.1 2 hrs Veh 21.6 ± 5.9 1.1 ± 0.5
2 hrs OVA 11.7 ± 3.7 115.7 ± 18.8 1 hr LPS 6.1 ± 2.2 102.1 ± 10.7 2 hrs ELA 72.6 ± 15.8 0.0 ± 0.0
4 hrs Veh 2.8 ± 1.6 181.0 ± 16.0 2 hrs Veh 0.5 ± 0.3 155.7 ± 66.9 6 hrs Veh 80.3 ± 30.5 1.2 ± 0.4
4 hrs OVA 144.1 ± 60.1 99.0 ± 8.7 2 hrs LPS 31.9 ± 9.6 71.3 ± 8.9 6 hrs ELA 267 ± 86.7 1.9 ± 0.9
6 hrs Veh 1.5 ± 0.9 175.7 ± 21.3 4 hrs Veh 0.2 ± 0.2 80.7 ± 16.6 24 hrs Veh 46.8 ± 22.4 0.9 ± 0.4
6 hrs OVA 977.1 ± 300.9 150.7 ± 25.9 4 hrs LPS 95.1 ± 24.5 80.0 ± 18.5 24 hrs ELA 382.1 ± 77.4 4.3 ± 2.5
8 hrs Veh 0.2 ± 0.2 173.9 ± 12.3 6 hrs Veh 0.0 ± 0.0 151.8 ± 37.8 48 hrs Veh 8.6 ± 2.3 0.0 ± 0.0
8 hrs OVA 1324.5 ± 293.2 178.1 ± 23.0 6 hrs LPS 110.0 ± 28.3 112.1 ± 10.5 48 hrs ELA 529.4 ± 174.5 4.3 ± 4.3
12 hrs Veh 1.6 ± 0.6 176.4 ± 31.9 8 hrs Veh 0.0 ± 0.0 141.5 ± 31.5 72 hrs Veh 1.1 ± 0.6 0.5 ± 0.2
12 hrs OVA 998.7 ± 312.2 195.2 ± 27.0 8 hrs LPS 80.6 ± 11.2 139.3 ± 11.7 72 hrs ELA 83.2 ± 9.1 0.6 ± 0.6
24 hrs Veh 0.7 ± 0.4 171.2 ± 15.9 12 hrs Veh 0.1 ± 0.1 100.5 ± 13.9 96 hrs Veh 1.9 ± 1.4 0.3 ± 0.3
24 hrs OVA 317.4 ± 141.3 390.1 ± 85.9 12 hrs LPS 41.3 ± 6.5 213.3 ± 10.4 96 hrs ELA 18.1 ± 8.4 1.7 ± 0.9
24 hrs Veh 0.1 ± 0.1 98.8 ± 15.9 168 hrs Veh 17.2 ± 14.1 0.4 ± 0.4
24 hrs LPS 7.9 ± 2.0 75.5 ± 12.9 168 hrs ELA 0.6 ± 0.4 0.3 ± 0.3Respiratory Research 2009, 10:72 http://respiratory-research.com/content/10/1/72
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cant and denoted with *. All the values are expressed as
mean ± s.e. mean of 6 observations.
Results
Cellular and biomarker inflammation in three different 
pre-clinical models of airways disease
The pre-clinical models of airways disease investigated
have been evoked using a different stimuli: ovalbumin,
LPS and elastase, and have previously been shown by our
group to each exhibit characteristics that are similar to that
observed in asthma [9,10], or COPD [13,12]. Figs. 1A, 2A,
3A and Table 2 show the inflammatory cell profiles
observed in these models, with the antigen model mim-
icking allergic eosinophilia and neutrophilia; the endo-
toxin model displaying predominately innate
neutrophilia, and the elastase-driven model featuring an
increase in lymphomononuclear cells and neutrophils.
Despite these three models each displaying an inflamma-
tory profile, interestingly, the cellular inflammation could
only be inhibited in the antigen model and the endotoxin
model, after treatment with an IKK-2 inhibitor (TPCA-1)
and budesonide, a steroid commonly used in the clinic to
treat patients. These two compounds have previously
been shown by our group to have no effect in the elastase
model, further highlighting the fact that these three mod-
els each exhibit a different inflammatory profile (Fig. 1B,
2B and 3B). Moreover, when NF-κB pathway activation
was investigated, the elastase model was observed to
exhibit no increase in levels of p65:DNA binding after
Antigen induced airway inflammation model Figure 1
Antigen induced airway inflammation model. Rats were sensitised on days 0, 14 and 21 with ovalbumin (OVA) (100 μg, 
i.p.) administered with aluminium hydroxide (100 mg, i.p.) and challenged with inhaled OVA (10 g/l, 30 minutes) or saline aero-
sol on day 28. BAL samples were taken at each time point for determination of A: eosinophil levels (neutrophil and LMN levels 
are shown in Table 2). B: Effect of an IKK-2 inhibitor (TPCA-1) or budesonide on BAL eosinophil levels. C: Levels of p65:DNA 
binding in the lung tissue. Statistical significance was determined using an unpaired t test with each independent group com-
pared to the vehicle control. If the variances of the two groups were significantly different then the Mann Whitney rank sum 
test was used. A p-value of less than 0.05 was taken as significant and denoted with *. All the values are expressed as mean ± 
s.e. mean of 6 observations.Respiratory Research 2009, 10:72 http://respiratory-research.com/content/10/1/72
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challenge, unlike the antigen model and the endotoxin
model (Fig. 1C, 2C and 3C).
Determination of MMP/TIMP mRNA levels in three 
distinct in vivo models of airways disease
In vivo model of antigen induced airway inflammation
In the antigen induced airway inflammation model,
which has been shown to exhibit aspects similar to the
inflammation observed in asthma, MMP-7 mRNA levels
were found to be increased as early as 4 hours after oval-
bumin challenge (Fig. 4A). MMP-8 and 9 mRNA levels
were found to have a similar profile, where levels were sig-
nificantly increased after ovalbumin (Fig. 4B and 4C).
Ovalbumin challenge was also demonstrated to increase
MMP-12 and 14 mRNA levels (Fig. 4E and Table 3 respec-
tively). Interestingly, MMP-11 mRNA levels were
observed to decrease after challenge (Fig. 4D), and MMP-
3, 10 and 13 mRNA levels were either BRDL or very low
(Table 3). Basal MMP-2 mRNA levels were measured at all
the time points, which appeared not to change after anti-
gen challenge, except at the 24 hour time point where a
significant decrease was observed after antigen challenge
(Table 3). Surprisingly, a significant increase in TIMP-1
and TIMP-3 mRNA levels were observed after treatment
(Fig. 4F and 4H), whereas a general decrease was observed
in TIMP-2 mRNA levels (Fig. 4G). TIMP-4 mRNA levels
were observed to be low and ovalbumin challenge
appeared to decrease these levels (Table 3).
Endotoxin induced airway neutrophilia model Figure 2
Endotoxin induced airway neutrophilia model. Rats were challenged with aerosolised endotoxin free saline or aero-
solised LPS (0.3 mg/ml) for 30 minutes. BAL samples were taken at each time point for determination of A: neutrophil levels 
(eosinophils and LMN levels are shown in Table 2). B: Effect of an IKK-2 inhibitor (TPCA-1) or budesonide on BAL neutrophil 
levels. C: Levels of p65:DNA binding in the lung tissue. Statistical significance was determined using an unpaired t test with each 
independent group compared to the vehicle control. If the variances of the two groups were significantly different then the 
Mann Whitney rank sum test was used. A p-value of less than 0.05 was taken as significant and denoted with *. All the values 
are expressed as mean ± s.e. mean of 6 observations.Respiratory Research 2009, 10:72 http://respiratory-research.com/content/10/1/72
Page 7 of 15
(page number not for citation purposes)
In vivo model of LPS induced neutrophilia
In the rat model of LPS induced airway neutrophilia,
MMP-7 mRNA levels were detected from 8 hours after LPS
challenge (Fig. 5A). The profile of MMP-8, 9 and 12
mRNA levels appear to be different to MMP-7, where
these levels were found to be significantly increased with
time after LPS challenge (Fig. 5B, C and 5E). Interestingly,
similar to the antigen model, MMP-11 mRNA levels were
also found to be significantly decreased after challenge
(Fig. 5D). There was no significant difference in MMP-14
mRNA levels after LPS challenge (Table 4). TIMP-1 mRNA
levels had a similar profile to MMP-8, 9 and 12, where a
significant increase in mRNA level was observed with time
(Fig. 5F). TIMP-2 and 3 mRNA levels were observed to be
significantly decreased at some of the time points after
LPS challenge (Fig. 5G and 5H). Similar to the antigen
model, MMP-2, 3, 10, 13 and TIMP-4 mRNA levels were
either BRDL, low or no significant difference was observed
between vehicle and treated groups (Table 4).
In vivo model of elastase driven experimental emphysema
MMP-8 mRNA levels were found to be increased at the
earlier time points after elastase treatment (Fig. 6B). The
profiles of MMP-7, 9, 12, 14 and TIMP-1 mRNA levels
were similar to each other in this model, as mRNA levels
were found to be highest 48 hours after elastase treatment
(Fig. 6A, C, E, Table 5 and Fig. 6F, respectively). Similar to
the antigen model and the endotoxin model, MMP-11
mRNA levels were also found to be decreased after treat-
ment (Fig. 6D). No significant difference was observed in
Elastase induced experimental emphysema model Figure 3
Elastase induced experimental emphysema model. Rats were given saline (1 ml/kg, i.t.) or PPE (120 U/kg, i.t.). BAL sam-
ples were taken at each time point for determination of A: LMN levels (neutrophil and eosinophil levels are shown in Table 2). 
B: Effect of an IKK-2 inhibitor (TPCA-1) or budesonide on BAL lymphomononuclear cell levels. C: Levels of p65:DNA binding 
in the lung tissue. Statistical significance was determined using an unpaired t test with each independent group compared to the 
vehicle control. If the variances of the two groups were significantly different then the Mann Whitney rank sum test was used. 
A p-value of less than 0.05 was taken as significant and denoted with *. All the values are expressed as mean ± s.e. mean of 6 
observations.Respiratory Research 2009, 10:72 http://respiratory-research.com/content/10/1/72
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TIMP-2 mRNA levels after elastase insult (Fig. 6G). TIMP-
3 mRNA levels were found to be highly expressed in all
three pre-clinical models investigated, and were observed
to be significantly increased, 6 hours after elastase treat-
ment (Fig. 6H). Similar to the other two models, MMP-2,
3, 10, 13 and TIMP-4 mRNA levels were also found to be
BRDL, low in all the groups, or no significant difference
was observed between vehicle and treated groups (Table
5).
Determination of MMP-9 levels in three distinct in vivo 
models of airways disease
MMP-9 levels were determined in the BAL from the anti-
gen model, LPS model and the elastase model, using
zymography. BAL MMP 9 levels were observed to be
increased with time after ovalbumin, LPS or elastase insult
(Fig. 7A, B and 7C respectively).
Discussion
There is a wealth of information in the literature speculat-
ing that MMPs may play a critical role in inflammatory
diseases, such as asthma and COPD. This is the first study
in the literature that compares the inflammatory profiles
in three distinct pre-clinical models, each evoked by a dif-
ferent stimulus to mimic some of the inflammatory char-
acteristics that are observed in asthma or COPD. The first
part of this study compares the profile of cellular inflam-
mation and inflammatory cytokines between the three
models. The data show that these three models each have
distinct inflammatory characteristics which are exhibited
in disease, for example, increased eosinophils in asthma
or increased neutrophils and lymphomononuclear cells
in inflammatory airways diseases, such as COPD. In addi-
tion, the inflammation in both the antigen model and the
endotoxin model were observed to be steroid-sensitive
and involve the IKK/NF-κB pathway, whereas the elastase
model, a model that we have previously demonstrated to
have structural lung changes, was shown to be steroid
resistant and without involvement of the IKK/NF-κB path-
way. This first part of the study demonstrated that the
three pre-clinical models investigated each have a differ-
ent inflammatory profile, and since many reports only
focus on the role of one particular MMP, and often only
in one model system, we were interested in comparing the
MMP/TIMP mRNA expression profiles between these dif-
ferent models. To enable this, we used designed and pur-
chased primers and probes for TaqMan Real Time PCR.
Interestingly, our data demonstrated that although the
three models of airways disease each have a very different
and distinct inflammatory profile, the expression profile
of lung MMPs 2, 7  10, 12  14, TIMP-1 and 4 mRNA levels
were similar in each model. We chose to use Real Time
PCR as there is a limited range of investigational tech-
niques that are commercially available for the range of rat
MMPs and TIMPs investigated in this study. To date, the
range of rat MMP and TIMP ELISAs for measuring MMPs/
TIMPs at the protein level remain very limited. One of the
available techniques that has been widely used by
researchers to investigate MMP-9 at the protein level, is
zymography. This technique uses the activity of MMP-9 to
assess levels of the mediator. In our study, the amounts of
MMP-9 measured with zymography appear to temporally
correlate with MMP-9 mRNA levels in all three models.
This would suggest that the mRNA profiling data estab-
lished in this manuscript is likely to be indicative of the
amounts of the same target at the protein level. However,
it should be noted that the profile of the different MMP/
TIMP mRNA levels obtained in this study may not be
equivalent to the activity status of the proteins investi-
gated, since MMPs are regulated at various intra- and
extracellular levels. Despite this, the data obtained from
this study provides very useful information about the
extensive range of MMPs and TIMPs investigated at the
molecular level, where tools are limited for investigation
at the protein level. To date, there does not appear to be
any information in the literature on the profile of the
Table 3: MMP mRNA levels in the in vivo model of antigen 
induced airway inflammation.
MMP-2 MMP-3 MMP-14 TIMP-4
2 hrs Vehicle 72.1 ± 10.2 BRDL 18.6 ± 2.3 0.3 ± 0.0
2 hrs Ovalbumin 84.3 ± 6.9 BRDL 33.8 ± 1.7
*
0.2 ± 0.1
4 hrs Vehicle 77.1 ± 11.7 BRDL 24.1 ± 4.0 0.3 ± 0.1
4 hrs Ovalbumin 71.3 ± 2.5 0.1 ± 0.0 28.7 ± 2.3 0.2 ± 0.0
6 hrs Vehicle 58.3 ± 11.5 BRDL 21.7 ± 3.6 0.3 ± 0.0
6 hrs Ovalbumin 73.0 ± 6.9 BRDL 40.9 ± 7.5
*
0.2 ± 0.1
8 hrs Vehicle 52.7 ± 3.7 BRDL 18.5 ± 2.5 0.6 ± 0.1
8 hrs Ovalbumin 64.1 ± 5 BRDL 43.5 ± 7.4
*
0.2 ± 0.1
*
12 hrs Vehicle 82.0 ± 9.7 0.2 ± 0.0 17.0 ± 3.1 0.6 ± 0.1
12 hrs Ovalbumin 71.3 ± 3.9 BRDL 50.7 ± 5.7
*
0.2 ± 0.0
*
24 hrs Vehicle 75.9 ± 5.5 0.1 ± 0.0 22.5 ± 2.1 0.3 ± 0.1
24 hrs Ovalbumin 48.3 ± 8.5
*
0.2 ± 0.0 42.0 ± 8.8 0.2 ± 0.1
*
A p-value of less than 0.05 was taken as significant and denoted with *. 
MMP-10 and 13 were BRDL.Respiratory Research 2009, 10:72 http://respiratory-research.com/content/10/1/72
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Figure 4 (see legend on next page)Respiratory Research 2009, 10:72 http://respiratory-research.com/content/10/1/72
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extensive range of MMPs and TIMPs investigated in this
study in these pre-clinical models of inflammation.
Three different strains of rats were used for the three dif-
ferent models since previous historical work performed by
our group used these strains in the development of these
"disease" models. An investigation of the MMP and TIMP
mRNA expression profile in the naïve rat lungs of the
three strains of rats investigated appeared to be similar,
suggesting that these strains were comparable (data not
shown). However, the differences that could exist
between the three different strains cannot be completely
ruled out.
It is believed that matrix remodelling is the result, in part,
of a shift in the balance between active MMPs versus
TIMPs, and it is thought that coordinated regulation of
these proteases and anti-proteases is required to maintain
tissue architecture [16]. Interestingly, this study demon-
strated not only an increase in proteases, but also an
increase in mRNA levels of TIMP-1, an anti-protease in
inflammatory conditions. However, there is evidence in
MMP mRNA levels in the in vivo model of antigen induced airway inflammation Figure 4 (see previous page)
MMP mRNA levels in the in vivo model of antigen induced airway inflammation. Rats were sensitised on days 0, 14 
and 21 with ovalbumin (OVA) (100 μg, i.p.) administered with aluminium hydroxide (100 mg, i.p.) and challenged with inhaled 
OVA (10 g/l, 30 minutes) or saline aerosol on day 28. Rats were sacrificed with an overdose of sodium pentobarbitone, and 
lung lobes were obtained for mRNA levels. MMP mRNA levels were determined by Real Time PCR (A: MMP-7; B: MMP-8; C: 
MMP-9; D: MMP-11; E: MMP-12; F: TIMP-1; G: TIMP-2 and H: TIMP-3). Table 3 shows the data for the remaining MMPs/TIMPs. 
Data were deemed to be BRDL, if the value was less than 0.1. MMP-10 and 13 were BRDL. Where the levels in the time-
matched vehicle controls were BRDL, statistical significance could not be determined. Statistical significance was determined 
using an unpaired t test with each independent group compared to the time matched vehicle control. If the variances of the 
two groups were significantly different then the Mann Whitney rank sum test was used. A p-value of less than 0.05 was taken 
as significant and denoted with *. All the values are expressed as mean ± s.e. mean of 6 observations.
Table 4: MMP mRNA levels in the in vivo model of LPS induced neutrophilic inflammation.
MMP-2 MMP-14 TIMP-4
1 hr Vehicle 90.3 ± 8.3 10.8 ± 0.8 0.3 ± 0.1
1 hr LPS 136.4 ± 35.2 13.2 ± 2.9 0.3 ± 0.1
2 hrs Vehicle 64.6 ± 1.7 9.7 ± 0.3 0.3 ± 0.04
2 hrs LPS 60.4 ± 7.8 10.5 ± 1.5 0.2 ± 0.1
4 hrs Vehicle 82.8 ± 6.8 11.1 ± 1.0 0.2 ± 0.1
4 hrs LPS 89.7 ± 7.7 11.8 ± 1.5 BRDL
6 hrs Vehicle 60.8 ± 13.4 10.4 ± 0.5 0.2 ± 0.04
6 hrs LPS 82.8 ± 10.7 14.1 ± 2.2 BRDL
8 hrs Vehicle 107.9 ± 22.4 19.5 ± 3.7 0.4 ± 0.1
8 hrs LPS 77.5 ± 12.1 23.9 ± 2.6 0.2 ± 0.1
12 hrs Vehicle 110.6 ± 13.0 22.9 ± 3.4 0.2 ± 0.03
12 hrs LPS 79.3 ± 6.8 21.0 ± 1.3 0.3 ± 0.1
24 hrs Vehicle 97.3 ± 13.8 20.8 ± 2.3 0.4 ± 0.1
24 hrs LPS 80.9 ± 3.9 ± 23.6 ± 1.6 0.3 ± 0.1
A p-value of less than 0.05 was taken as significant and denoted with *. MMP-3, 10 and 13 were BRDL.Respiratory Research 2009, 10:72 http://respiratory-research.com/content/10/1/72
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MMP mRNA levels in the in vivo model of LPS induced neutrophilic inflammation Figure 5 (see previous page)
MMP mRNA levels in the in vivo model of LPS induced neutrophilic inflammation. Rats were challenged with aero-
solised endotoxin free saline or aerosolised LPS (0.3 mg/ml) for 30 minutes, and were sacrificed with an overdose of sodium 
pentobarbitone, and lung lobes were obtained for mRNA levels. MMP mRNA levels were determined by Real Time PCR (A: 
MMP-7; B: MMP-8; C: MMP-9; D: MMP-11; E: MMP-12; F: TIMP-1; G: TIMP-2 and H: TIMP-3). All the values are expressed as 
mean ± s.e. mean of 6 observations. Data in the graphs are expressed as relative units. Table 4 shows the data for the remain-
ing MMPs/TIMPs. Data were deemed to be BRDL, if the value was less than 0.1. MMP-3, 10 and 13 were BRDL. Where the lev-
els in the time-matched vehicle controls were BRDL, statistical significance could not be determined. Statistical significance was 
determined using an unpaired t test with each independent group compared to the time matched vehicle control. If the vari-
ances of the two groups were significantly different then the Mann Whitney rank sum test was used. A p-value of less than 0.05 
was taken as significant and denoted with *. All the values are expressed as mean ± s.e. mean of 6 observations.
Table 5: MMP mRNA levels in the in vivo model of elastase driven experimental emphysema.
MMP-2 MMP-14 TIMP-4
2 hrs Vehicle 162.0 ± 14.7 38.4 ± 3.2 1.2 ± 0.2
2 hrs Elastase 168.4 ± 20.4 36.0 ± 2.5 0.7 ± 0.2
6 hrs Vehicle 76.9 ± 8.3 25.0 ± 3.3 0.5 ± 0.1
6 hrs Elastase 86.6 ± 8.3 36.6 ± 4.9 0.7 ± 0.1
24 hrs Vehicle 84.9 ± 10.9 18.3 ± 3.6 0.4 ± 0.04
24 hrs Elastase 59.7 ± 7.7 18.6 ± 2.4 0.2 ± 0.1
*
48 hrs Vehicle 70.8 ± 16.6 9.4 ± 2.0 0.5 ± 0.1
48 hrs Elastase 60.6 ± 4.1 42.2 ± 6.1
*
0.2 ± 0.1
*
72 hrs Vehicle 90.7 ± 9.3 15.5 ± 1.7 0.5 ± 0.1
72 hrs Elastase 74.7 ± 6.2 36.0 ± 5.7
*
0.3 ± 0.1
96 hrs Vehicle 95.6 ± 9.3 17.0 ± 2.4 0.6 ± 0.1
96 hrs Elastase 100.9 ± 11.1 23.5 ± 4.7 0.4 ± 0.05
168 hrs Vehicle 61.9 ± 5.9 16.8 ± 3.2 0.3 ± 0.1
168 hrs Elastase 66.0 ± 8.2 28.8 ± 5.2 0.2 ± 0.1
A p-value of less than 0.05 was taken as significant and denoted with *. MMP-3, 10 and 13 were BRDL.Respiratory Research 2009, 10:72 http://respiratory-research.com/content/10/1/72
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MMP mRNA levels in the in vivo model of elastase driven experimental emphysema Figure 6
MMP mRNA levels in the in vivo model of elastase driven experimental emphysema. Rats were given saline (1 ml/
kg, i.t.) or PPE (120 U/kg, i.t.) and were sacrificed with an overdose of sodium pentobarbitone, and lung lobes were obtained 
for mRNA levels. MMP mRNA levels were determined by Real Time PCR (A: MMP-7; B: MMP-8; C: MMP-9; D: MMP-11; E: 
MMP-12; F: TIMP-1; G: TIMP-2 and H: TIMP-3). Table 5 shows the data for the remaining MMPs/TIMPs. Data were deemed to 
be BRDL, if the value was less than 0.1. MMP-3, 10 and 13 were BRDL. Where the levels in the time-matched vehicle controls 
were BRDL, statistical significance could not be determined. Statistical significance was determined using an unpaired t test 
with each independent group compared to the time matched vehicle control. If the variances of the two groups were signifi-
cantly different then the Mann Whitney rank sum test was used. A p-value of less than 0.05 was taken as significant and 
denoted with *. All the values are expressed as mean ± s.e. mean of 6 observations.Respiratory Research 2009, 10:72 http://respiratory-research.com/content/10/1/72
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the literature suggesting that an over-expression of anti-
protease could be due to the host's response to an increase
in MMP, in an attempt to control MMP activity and retain
extra cellular matrix integrity [17], which could possibly
explain the increased TIMP-1 observed. There has also
been evidence in the literature of elevated TIMP-1 levels,
when investigated in the sputum of COPD patients
[18,19]. The study by Mercer et al [19] demonstrated
TIMP-1 levels to be increased in the sputum of stable
COPD patients prior to exacerbations, but during exacer-
bations, MMP-9 levels were significantly increased, so tip-
ping the balance in favour of MMP-9. Conversely, the
profiles of TIMP-2, 3 and 4 mRNA levels were observed to
be decreased overall in the models investigated, except for
TIMP-3 levels in the elastase model.
Conclusion
The findings of this study show that a range of MMPs are
upregulated in the three different models investigated.
Despite the fact that the kinetics of some of the MMP/
TIMP expression were different, the overall MMP/TIMP
profile is surprisingly similar between the three different
pre-clinical models of airways disease, in that the same
MMPs/TIMPs were generally increased or decreased in all
three models. It could therefore be speculated that in a
particular disease, it maybe a complex network of MMPs,
rather than an individual MMP, together with inflamma-
tory cytokines and other mediators, that results in the dis-
tinct phenotype of inflammatory diseases, such as asthma
and COPD. To our knowledge, this study is the first to
investigate such an extensive range of MMPs and TIMPs in
a range of different models of inflammation. Overall, we
BAL MMP-9 levels in three in vivo models of lung inflammation by zymography Figure 7
BAL MMP-9 levels in three in vivo models of lung inflammation by zymography. A: BAL MMP-9 levels in the antigen 
model: rats were sensitised on days 0, 14 and 21 with ovalbumin (OVA) (100 μg, i.p.) administered with aluminium hydroxide 
(100 mg, i.p.) and challenged with inhaled OVA (10 g/l, 30 minutes) or saline aerosol on day 28. B: BAL MMP-9 levels in the LPS 
model: rats were challenged with aerosolised endotoxin free saline or aerosolised LPS (0.3 mg/ml) for 30 minutes. C: BAL 
MMP-9 levels in the elastase model: rats were given saline (1 ml/kg, i.t.) or PPE (120 U/kg, i.t.). All rats were sacrificed with an 
overdose of sodium pentobarbitone, and BAL was taken for MMP-9 analysis by zymography. Statistical significance was deter-
mined using an unpaired t test with each independent group compared to the time matched vehicle control. If the variances of 
the two groups were significantly different then the Mann Whitney rank sum test was used. A p-value of less than 0.05 was 
taken as significant and denoted with *. All the values are expressed as mean ± s.e. mean of 6 observations.Publish with BioMed Central    and   every 
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believe this exciting data may provide very useful informa-
tion necessary to understand the role of various MMPs
and TIMPs in inflammatory airway diseases. Information
regarding the specific pattern of MMPs/TIMPs involved in
"disease" conditions may be useful for the development
of novel therapeutics without the side effect profile of
non-selective, broad-spectrum MMP inhibitors.
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